NEWS: SEPTEMBER 2007

-09/07/2007-

FDA Questions Data On Amgen, J&J Drugs. To read article click here.

Alnylam Pharmaceuticals Inc. and Isis Pharmaceuticals Inc. form joint venture: Regulus Therapeutics LLC. To read article click here.

-09/06/2007-

GlaxoSmithKline Plc. turns down Theravance Inc.'s gastrointestinal tract disorder program. To read article click here.

Exelixis and Dow Chemical sign crop genetics deal. To read article click here.

FDA decision on Encysive Pharmaceuticals Inc.'s drug Thelin: No go. To read article click here.

Johnson & Johnson abandons anti-anemia drug Procrit. To read article click here.

Introgen Therapeutics Inc. and Moffitt Cancer Center to advance INGN 225 to Phase II trials for metastatic small-cell lung cancer treatment. To read article click here.

llumina Inc. launches the Infinium HumanLinkage-12 Genotyping BeadChip. To read article click here.

-09/05/2007-

Dyax Corp. and Bayer Schering Pharma AG form drug discovery partnership. To read article click here.

Poniard Pharmaceuticals receives FDA fast track designation for Picoplatin for treatment of small cell lung cancer. To read article click here.

-09/04/2007-

ViaCell Inc. and EMD Serono Inc. form vitro fertilization partnership. To read article click here.

Isis Pharmaceuticals Inc. initiates Phase I clinical study of ISIS 325568 targeting glucagon receptor for Type 2 diabetes treatment. To read article click here.

-09/03/2007-

Merck KGaA submits broaden Erbitux application in Europe. To read article click here.